Key result
Combination therapy with rosuvastatin, candesartan, and hydrochlorothiazide significantly reduced the risk of the first co-primary cardiovascular outcome (HR 0.71) compared to dual placebo.
Why the study?
Does rosuvastatin, candesartan plus hydrochlorothiazide, or their combination reduce cardiovascular events in intermediate-risk participants?
RCT (n=12,705)
2-by-2 factorial
Yes
Does rosuvastatin, candesartan plus hydrochlorothiazide, or their combination reduce cardiovascular events in intermediate-risk participants?
In intermediate-risk individuals, statin therapy (with or without antihypertensives) reduces cardiovascular events, whereas antihypertensive therapy alone does not provide significant benefit.
The HOPE-3 investigators enrolled 12,705 intermediate-risk participants in 21 countries in a 2-by-2 factorial trial. Subjects were randomized to receive a fixed dose of rosuvastatin or placebo, candesartan plus hydrochlorothiazide daily or placebo, and a third group received combination of antihypertensive and statins versus double placebo. The median follow-up was 5.6 years. The combination of antihypertensive and statin therapy was associated with a significantly lower rate of cardiovascular events than dual placebo. Statin therapy alone was also associated with improved outcome, while antihypertensive therapy had no added benefit compared to placebo.
No takes yet. Share an insight, caveat, or question.
Jassim Al Suwaidi (2016) conducted an RCT in Intermediate cardiovascular risk (n=12,705). Rosuvastatin, candesartan, and hydrochlorothiazide vs. Dual placebo was evaluated on First co-primary outcome (HR 0.71, 95% CI 0.56-0.90, p=0.005). Combination therapy with rosuvastatin, candesartan, and hydrochlorothiazide significantly reduced the risk of the first co-primary cardiovascular outcome (HR 0.71) compared to dual placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: